Collaboration and License Agreements - Lilly (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Feb. 28, 2022
Collaborative Agreements disclosures
Aggregate amount of transaction price allocated to remaining performance obligations	$ 47,500
Revenue from contract with customer	49,869	$ 38,078
Amount of obligation included in long-term deferred revenue	34,055		$ 36,355
Lilly
Collaborative Agreements disclosures
License agreement upfront payment receivable				$ 13,000
License agreement additional payment receivable				19,500
License agreement, target selection fees and development, regulatory and commercial milestone payments receivable				$ 1,700,000
Lilly | Initial targets
Collaborative Agreements disclosures
Revenue from contract with customer	9,200		18,400
Lilly | Additional targets
Collaborative Agreements disclosures
License agreement additional payment receivable			$ 13,000
Lilly | Material rights to obtain licenses to replacement targets
Collaborative Agreements disclosures
Amount of obligation included in long-term deferred revenue	$ 7,600